From the Journals

World Trade Center responders face greater cancer burden, including greater risk of multiple myeloma

View on the News

World Trade Center exposure and myeloma – correlation or causation?

When the heroes of the World Trade Center are diagnosed with even a common cancer, there is a natural tendency to assume that the diagnosis is the result of their service during the disaster. However, it is important to appreciate that the firefighting profession is known to be associated with higher risks of monoclonal gammopathy of undetermined significance and multiple myelomas, compared with the general population.

Given that, it would have been preferable to compare the World Trade Center–exposed populations with an equally intensively screened, age-matched cohort of firefighters from another major city.

If we apply Sir Richard Doll’s rule that a single epidemiologic study cannot be persuasive until the lower bound of the 95% confidence interval is greater than three, the relative risks in the study by Landgren and colleagues are too small to be persuasive.

The predicted increases in cancers of the prostate, thyroid, and myeloma are interesting, but these have also been previously reported in firefighters from other cities.

Despite this, we owe it to these men and women to find the truth and determine the illnesses that are associated with their service.

Otis W. Brawley, MD, is chief medical and scientific officer and executive vice president of the American Cancer Society and a professor at Emory University, Atlanta. These comments are taken from an accompanying editorial (JAMA Oncology. 2018 April 26. doi: 10.1001/jamaoncol.2018.0498.) No conflicts of interest were declared.


 

FROM JAMA ONCOLOGY


The first study was supported by the National Institute of Occupational Safety and Health; no conflicts of interest were declared.

The second study was supported by the V Foundation for Cancer Research, the Byrne Fund for the benefit of Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, the Albert Einstein Cancer Center, and the National Institute for Occupational Safety and Health; no conflicts of interest were declared.

SOURCE: Zeig-Owens R et al. JAMA Oncology. 2018 April 26. doi: 10.1001/jamaoncol.2018.0504. Landgren O et al. JAMA Oncology. 2018 April 16. doi: 10.1001/jamaoncol.2018.0509.

Pages

Recommended Reading

CDK inhibitor synergizes with venetoclax in CLL
MDedge Hematology and Oncology
Improving education for pediatric cancer caregivers
MDedge Hematology and Oncology
Potential therapeutic target for type of AML
MDedge Hematology and Oncology
Drug receives orphan designation for ALL
MDedge Hematology and Oncology
Exercise linked to risk of death in cancer patients
MDedge Hematology and Oncology
GO approved to treat AML in Europe
MDedge Hematology and Oncology
Art education benefits blood cancer patients
MDedge Hematology and Oncology
BET inhibitor has lasting effects in AML, MM
MDedge Hematology and Oncology
Inhibitor outperforms rivals in leukemia, lymphoma
MDedge Hematology and Oncology
Study reveals gene variants that predispose kids to ALL
MDedge Hematology and Oncology